한빛사논문
- 조회441
Yoo, Yun J.; Wilkins, Kenneth J.; Alakwaa, Fadhl; Liu, Feifan; Torre-Healy, Luke A.; Krichevsky, Spencer; Hong, Stephanie S.; Sakhuja, Ankit; Potu, Chetan K.; Saltz, Joel H.; Saran, Rajiv; Zhu, Richard L.; Setoguchi, Soko; Kane-Gill, Sandra L.; Mallipattu, Sandeep K.; He, Yongqun; Ellison, David H.; Byrd, James B.; Parikh, Chirag R.; Moffitt, Richard A.*,a; Koraishy, Farrukh M.*,a; on behalf of the N3C and RECOVER Consortia
YJY: Department of Biology, Stony Brook University, Stony Brook, NY
KJW: Biostatistics Program, Office of the Director, National Institute of Diabetes & Digestive & Kidney Diseases; Department of Preventive Medicine & Biostatistics, F. Edward Hébert School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD
FA: Department of Internal Medicine, Nephrology Division, University of Michigan, Ann Arbor, MI
FL: Department of Population and Quantitative Health Sciences, University of Massachusetts Chan Medical School, Worcester, MA
LATH: Department of Biomedical Informatics, Stony Brook University, Stony Brook, NY
SK: Department of Biomedical Informatics, Stony Brook University, Stony Brook, NY
SSH: Biomedical Informatics and Data Science Section, Department of General Internal Medicine, Johns Hopkins University School of Medicine, Baltimore, MD
AS: Section of Cardiovascular Critical Care, Dept of Cardiovascular and Thoracic Surgery, West Virginia University, Morgantown, WV
CKP: Renaissance School of Medicine, Stony Brook University, Stony Brook, NY
JHS: Department of Biomedical Informatics, Stony Brook University, Stony Brook, NY
RS: Division of Nephrology, Department of Internal Medicine and Department of Epidemiology, University of Michigan, Ann Arbor, MI
RLZ: Institution for Clinical and Translational Research, Johns Hopkins University School of Medicine, Baltimore, MD
SS: Department of Medicine and Epidemiology, Rutgers Robert Wood Johnson Medical School and School of Public Health, New Brunswick, NJ
SLKG: Department of Pharmacy and Therapeutics, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA
SKM: Division of Nephrology and Hypertension, Department of Medicine, Stony Brook University, Stony Brook, and Northport VAMC, Northport, NY, USA
YH: Unit for Laboratory Animal Medicine, Department of Microbiology and Immunology, and Center for Computational Medicine and Bioinformatics, University of Michigan Medical School, Ann Arbor, MI
DHE: Oregon Clinical & Translational Research Institute, Oregon Health & Science University, Portland OR and VA Portland Health Care System, Portland, OR
JBB: Division of Cardiovascular Medicine, Department of Medicine, University of Michigan, Ann Arbor, MI
CRP: Johns Hopkins School of Medicine, Baltimore, MD
RAM: Department of Biomedical Informatics, Cancer Center, Department of Pathology, Department of Pharmacological Sciences, Stony Brook University, Stony Brook, NY
FMK: Division of Nephrology and Hypertension, Department of Medicine, Stony Brook University, Stony Brook, and Northport VAMC, Northport, NY, USA
acorrespondence should be addressed: Farrukh M. Koraishy and Richard A. Moffitt
*These authors jointly supervised this work.
Abstract
Background: Acute kidney injury (AKI) is associated with mortality in patients hospitalized with COVID-19, however, its incidence, geographic distribution, and temporal trends since the start of the pandemic are understudied.
Methods: Electronic health record data were obtained from 53 health systems in the United States (US) in the National COVID Cohort Collaborative (N3C). We selected hospitalized adults diagnosed with COVID-19 between March 6th, 2020, and January 6th, 2022. AKI was determined with serum creatinine and diagnosis codes. Time was divided into 16-week periods (P1-6) and geographical regions into Northeast, Midwest, South, and West. Multivariable models were used to analyze the risk factors for AKI or mortality.
Results: Out of a total cohort of 336,473, 129,176 (38%) patients had AKI. 54,714 (17%) lacked a diagnosis code but had AKI based on the change in serum creatinine. Similar to patients coded for AKI, these patients had higher mortality compared to those without AKI. The incidence of AKI was highest in P1 (47%; 23097/48947), reduced in P2 (37%; 12102/32513), and relatively stable thereafter. Compared to the Midwest, the Northeast, South, and West had higher adjusted odds of AKI in P1. Subsequently, the South and West regions continued to have the highest relative AKI odds. In multivariable models, AKI defined by either serum creatinine or diagnostic code, and the severity of AKI was associated with mortality.
Conclusions: The incidence and distribution of COVID-19-associated AKI have changed since the first wave of the pandemic in the US.
논문정보
- Research article
- 2023년 05월 (BRIC 등록일 2023-05-30)
- 국외 연구진
- 의약학 > 종양의학
댓글 작성 로그인
팝업 닫기관련 링크
관련분야 연구자보기
소속기관 논문보기
관련분야 논문보기
해당논문 저자보기
